Search
Search Results
##search.searchResults.foundPlural##
-
PATHOGENESIS OF MALARIA IN TISSUES AND BLOOD
4300PDF: 1859HTML: 17705 -
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10220PDF: 6117HTML: 21737 -
INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?
3116PDF: 963HTML: 1986 -
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2703PDF: 810HTML: 6491Untitled: 204Untitled: 167Untitled: 163Untitled: 186 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1189PDF: 449HTML: 18539Figure 1: 151Figure 2: 132Figure 3: 152Figure 4: 185Figure 5: 153 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1712PDF: 775HTML: 10200Figures 1,2,3: 150 -
THE ROLE OF INFECTION IN THE PATHOGENESIS OF VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE.
5036PDF: 1284HTML: 2721Cover letter: 173 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2148PDF: 823HTML: 2057 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1662PDF: 914HTML: 126 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2491PDF: 1562HTML: 2333Table1: 172 -
ROLE OF CYTOKINES AS MOLECULAR MARKER OF DENGUE SEVERITY
3018PDF: 1107HTML: 361 -
THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE
6150PDF: 2025HTML: 13963Untitled: 183figure: 159 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2501PDF: 769HTML: 5172 -
-
-
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3638PDF: 1404HTML: 455Figures . Eliassian: 198 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3416PDF: 2323HTML: 1401 -
-
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1214PDF: 764HTML: 110 -
Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS
793PDF: 614HTML: 186 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2423PDF: 804HTML: 8784Efremov 1: 204Efremov 2: 161 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2961PDF: 827HTML: 7148Kost Fig1: 163Kost Fig 2: 153Kost Fig3: 149Kost Fig 4: 166Kost Fig5: 162Kost fig 6: 149 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1318PDF: 782HTML: 3100 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2523PDF: 1026HTML: 94 -
EVALUATION OF THE PLASMA MICRO RNA EXPRESSION LEVELS IN SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
1319PDF: 654HTML: 1063Untitled: 162Untitled: 128Untitled: 112Untitled: 132Untitled: 139 -
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
6627PDF: 3530HTML: 717 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
1846PDF: 762HTML: 204 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1405PDF: 885HTML: 207 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2656PDF: 1731HTML: 3622Pellagatti Fig 1: 182Pellagatti Fig. 2: 181 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3088PDF: 1371HTML: 5830Fig1-Ag-Pil: 191Ag-Pil Fig.2: 194 -
-
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
3949PDF: 1509HTML: 791 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1728HTML: 1335PDF: 1003 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1956PDF: 1567HTML: 344 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1227PDF: 807HTML: 1022Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 151







